• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Exchange Listing Client, Neuraxis, Inc., Successfully Completes Its Initial Public Offering and NYSE Listing

By: EXCHANGE LISTING, LLC via GlobeNewswire
August 10, 2023 at 09:00 AM EDT

Fort Lauderdale, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Exchange Listing, LLC is pleased to announce the successful initial public offering and NYSE American listing for its client, NeurAxis, Inc. ("NeaurAxis" or the "Company") (NYSE American: NRXS) on August 9, 2023. As a result of this milestone achievement, NeurAxis’ common stock commenced trading on the NYSE American exchange under the ticker symbol 'NRXS.' The offering is expected to close on August 11, 2023 subject to the satisfaction of customary closing conditions.

Concurrent with the listing, NeurAxis announced the pricing of its underwriter's initial public offering of 1,098,667  shares of common stock at a price of $6 per share. In addition, NeurAxis has granted the underwriters a 45-day option to purchase up to an additional 164,800 of its common shares at the offering price of $6 per share, less the underwriting discounts and commissions, to cover over-allotments, if any. The gross proceeds to NeurAxis from the offering, before deducting the underwriting discounts, commissions, and offering expenses, are expected to be approximately $6,592,000.

Alexander Capital L.P. acted as sole book-running manager for the offering. Lucosky Brookman LLP served as counsel to NeurAxis. Carmel, Milazzo & Feil LLP served as counsel to the underwriters.

NeurAxis, Inc., is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. The company is dedicated to advancing science and leveraging evidence-based medicine to drive the adoption of its IB-Stim therapy, which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim is FDA-cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents 11-18 years old.  Additional clinical trials of PENFS in multiple pediatric and adult conditions with large unmet healthcare needs are currently underway.

“The Exchange Listing team has been an invaluable tool over the years of working together toward this IPO. We are so grateful to the team for their unwavering support and expertise in helping us achieve this huge milestone that has the potential to impact many lives in the future,” said Brian Carrico, president, and CEO of NeurAxis.

“We feel so proud to have been a part of this achievement. NeurAxis is changing the lives of countless children and their families. NeurAxis uses superior science, and evidence-based research, and building continually works to provide an unparalleled body of clinical evidence, which is necessary for adoption by the medical and scientific community. Congratulations to Brian and his team for their hard work and perseverance,” said Peter Goldstein, CEO of Exchange Listing.

Exchange Listing, LLC provides growth companies with cost-effective and efficient direct access to one-stop solutions in strategic planning and implementation of listing and uplisting on senior exchanges such as the Nasdaq or NYSE. Their focus on company-specific structuring to meet listing requirements makes them the primary point of contact with the exchange, investment bankers, and lawyers throughout the listing process. With extensive experience in investment banking, securities law, corporate governance, and business management, Exchange Listing and its strategic partners facilitate clients' listing and capital markets objectives.

For further information, please contact:

Peter Goldstein Email: Peter@exchangelistingllc.com Phone: (954) 998-5510

Visit the Company's Website: https://exchangelistingllc.com/


Primary Logo

More News

View More
Johnson & Johnson's M&A Strategy Is the Real Story for Investors
Today 12:04 EDT
Via MarketBeat
Tickers JNJ KVUE PTGX
Tesla: Some Analysts Are Calling for A 30% Drop—Time to Panic?
Today 9:36 EDT
Via MarketBeat
Topics Artificial Intelligence
Tickers TSLA
Hedge Funds Flip on the Dollar—A Buy Signal for These 3 Stocks?
Today 8:35 EDT
Via MarketBeat
Topics Bonds Stocks World Trade
Tickers ABNB DAL DOW HD
Happy Third Birthday to the Bull Market
Today 8:22 EDT
Via MarketBeat
Topics Artificial Intelligence Stocks
Tickers NVDA PLTR TSLA
MarketBeat Week in Review – 10/13 - 10/17
Today 7:00 EDT
Via MarketBeat
Topics Artificial Intelligence Economy World Trade
Tickers ACHR AMZN APLD APP ASTS CRM

Recent Quotes

View More
Symbol Price Change (%)
AMZN  213.04
-1.43 (-0.67%)
AAPL  252.30
+4.85 (1.96%)
AMD  233.08
-1.48 (-0.63%)
BAC  51.28
+0.84 (1.67%)
GOOG  253.79
+1.91 (0.76%)
META  716.91
+4.84 (0.68%)
MSFT  513.58
+1.97 (0.39%)
NVDA  183.16
+1.35 (0.74%)
ORCL  291.31
-21.69 (-6.93%)
TSLA  439.31
+10.56 (2.46%)
FinancialContent
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap